Arrowhead Pharmaceuticals, INC. (ARWR) — 8-K Filings

8-K Filings (12)

• 8-K Filing — Nov 18, 2025
• Arrowhead Pharma inks $1.2B deal with Horizon for plozasiran — Sep 12, 2025 Risk: medium
  Arrowhead Pharmaceuticals, Inc. (ARWR) announced on September 11, 2025, that it has entered into a collaboration and license agreement with Horizon Therapeutics
• 8-K Filing — Sep 11, 2025
• Arrowhead Pharmaceuticals Files 8-K Report — Sep 2, 2025 Risk: low
  On September 2, 2025, Arrowhead Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the
• Arrowhead Pharma Reports Executive & Director Changes — Apr 15, 2025 Risk: medium
  On April 11, 2025, Arrowhead Pharmaceuticals, Inc. reported changes in its executive and director positions. The company announced the departure of certain offi
• Arrowhead Pharmaceuticals Files 8-K — Mar 19, 2025 Risk: low
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on March 19, 2025, reporting on matters submitted to a vote of security holders and financial statements as of Marc
• Arrowhead Pharma Files 8-K: Board & Executive Compensation Changes — Feb 7, 2025 Risk: medium
  Arrowhead Pharmaceuticals, Inc. announced on February 7, 2025, changes in its board of directors and executive compensation. The filing details the departure of
• Arrowhead Pharmaceuticals Appoints New Director — Dec 18, 2024 Risk: low
  Arrowhead Pharmaceuticals, Inc. announced on December 17, 2024, that its Board of Directors appointed Dr. Christopher M. Marlett as a new director, effective De
• Arrowhead Pharmaceuticals Files 8-K — Mar 19, 2024 Risk: low
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on March 19, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filin
• Arrowhead Pharma Files 8-K on Officer Compensatory Arrangements — Feb 22, 2024 Risk: medium
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 21, 2024. The filing pertains to Item 5.02, spec
• Arrowhead Pharma Reports Executive Compensation Changes — Jan 22, 2024
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on January 22, 2024, reporting an event that occurred on January 16, 2024. This filing indicates a change in compen
• Arrowhead Pharma Enters Material Definitive Agreement — Jan 4, 2024
  Arrowhead Pharmaceuticals, Inc. filed an 8-K on January 4, 2024, reporting an "Entry into a Material Definitive Agreement" as of January 2, 2024. This filing in

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX